InsidersTradesSigma
Track the Monopar Therapeutics Inc. share price and the full directors' dealings record of the company, a publicly traded company based in United States. Shares trade on the US market, under the oversight of SEC (Form 4). Market capitalisation: €764.8m. The latest transaction was filed on 26 August 2026 (Notice of proposed sale (Form 144)). Among the most active insiders: Arthur Klausner. The full history is accessible without an account.
Analysts rate Monopar Therapeutics Inc. Strong Buy (bullish), based on 13 analysts. Average price target: US$126.31.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
5 of 5 declarations
Monopar Therapeutics Inc. es una empresa biofarmacéutica centrada en el desarrollo de tratamientos para cánceres raros y difíciles de tratar. Emplea enfoques innovadores para mejorar los resultados de los pacientes.